Deal Watch: Sanofi Offloads Established Products, Lilly Testing 3D-Printed Drugs

 
• By Mandy Jackson and Mary Jo Laffler
  
Generate a summary of this article
Listen to this article
Beta

Specialty pharma Neuraxpharm is taking on 38 mature brands from Sanofi, in CNS, pain and vascular diseases. Lilly is working with Triastek on 3D printing technology for targeted release of drugs in specific regions of the gastrointestinal tract.

Deal Watch 2021
• Source: Shutterstock

Central nervous system specialist Neuraxpharm Arzneimittel GmbH, headquartered in Dusseldorf and Barcelona, announced 12 July that it is strengthening its position as a leading European specialty pharmaceutical company focused on the central nervous system by acquiring two product portfolios for CNS disorders, pain and vascular diseases from French pharma Sanofi. Neuraxpharm is active in 19 European counties, and the Sanofi products will bring it into more than 50 countries globally.

The CNS portfolio covers psychiatry and neurology indications, including depression, anxiety, psychosis, alcohol dependence, myasthenia gravis and Parkinson disease, with...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.